A ‘phenomenal’ pill taken twice a day could protect millions of heart disease patients from an early grave.
Rivaroxaban slashes the risk of dying from the world’s leading killer by 22 per cent when taken with aspirin, research has found.
In clinical experiments, the tablet, which is already used for other cardiovascular problems, also reduced strokes by 42 per cent.
The ‘ground-breaking’ trial, based on 27,000 patients from 33 countries, has since been halted – 12 months ahead of schedule.
Dr Derek Connolly, a heart consultant at Birmingham City Hospital who was involved in the global study, welcomed the breakthrough.